• 1. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 4. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

• Solvents and Organic Chemicals Organic Compounds Benzenoids Tetralins Tetralins
• Solvents and Organic Chemicals Organic Compounds Benzenoids Tetralins

Research Brief on 3,4-Dihydro-3,4-dihydroxynaphthalen-1(2H)-one (CAS: 1220891-22-4): Recent Advances and Applications

3,4-Dihydro-3,4-dihydroxynaphthalen-1(2H)-one (CAS: 1220891-22-4) is a naphthalene-derived compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural features and potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive molecules, as well as its direct pharmacological properties. This research brief synthesizes the latest findings on this compound, highlighting its mechanisms of action, synthetic pathways, and emerging applications in drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry investigated the compound's potential as a precursor for the synthesis of novel polycyclic aromatic hydrocarbons (PAHs) with anti-inflammatory properties. The researchers demonstrated that 3,4-Dihydro-3,4-dihydroxynaphthalen-1(2H)-one could be efficiently converted into derivatives that selectively inhibit cyclooxygenase-2 (COX-2), a key enzyme in the inflammatory cascade. The study reported a 40% reduction in pro-inflammatory cytokines in murine models, suggesting its promise as a scaffold for developing next-generation anti-inflammatory agents.

In the realm of oncology, a team from the University of Cambridge (2024) identified this compound as a potent modulator of the Nrf2-Keap1 pathway, which plays a critical role in cellular defense against oxidative stress. Their findings, published in Cancer Research, revealed that derivatives of 3,4-Dihydro-3,4-dihydroxynaphthalen-1(2H)-one exhibited selective cytotoxicity against pancreatic cancer cell lines (IC50 = 2.3 μM) while showing minimal effects on normal cells. The study employed advanced molecular docking simulations to elucidate the compound's binding interactions with Keap1, providing a structural basis for further optimization.

From a synthetic chemistry perspective, recent advancements have focused on improving the efficiency of producing 3,4-Dihydro-3,4-dihydroxynaphthalen-1(2H)-one. A 2024 Organic Process Research & Development paper detailed a novel biocatalytic approach using engineered E. coli strains expressing naphthalene dioxygenase, achieving an 85% yield with significantly reduced environmental impact compared to traditional chemical synthesis methods. This green chemistry breakthrough addresses previous challenges in scalability and sustainability for industrial production.

Pharmacokinetic studies have also progressed, with a recent Xenobiotica publication (2024) reporting improved formulations of the compound using cyclodextrin-based delivery systems. These formulations demonstrated enhanced oral bioavailability (F = 65%) and extended plasma half-life (t1/2 = 8.2 hours) in primate models, overcoming previous limitations related to poor solubility and rapid metabolism.

Looking forward, the compound's unique dihydroxynaphthalenone structure continues to inspire novel applications. Current clinical investigations are exploring its potential in neurodegenerative diseases, leveraging its dual antioxidant and anti-aggregation properties against amyloidogenic proteins. As research progresses, 3,4-Dihydro-3,4-dihydroxynaphthalen-1(2H)-one (CAS: 1220891-22-4) stands poised to make significant contributions across multiple therapeutic areas, supported by both its inherent bioactivity and versatility as a synthetic building block.

• 161219-30-3(1H-Inden-1-one, 2,3-dihydro-3-hydroxy-, (3R)-)
• 26976-59-0(1H-Inden-1-one,2,3-dihydro-3-hydroxy-)
• 148021-80-1(17H-Cyclopenta[a]phenanthren-17-one,3,4,15,16-tetrahydro-3,4-dihydroxy-)
• 628713-37-1((3S,4R)-3,4-dihydroxy-3,4-dihydronaphthalen-1(2H)-one)
• 21032-12-2(4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-one)
• 501687-07-6(1-Propanone, 3-hydroxy-3-(2-methylphenyl)-1-phenyl-)
• 606492-26-6(3,4-Dihydroxy-3,4-dihydronaphthalen-1(2H)-one)
• 1488119-94-3((2S,3S)-12-hydroxypterosin Q)
• 54797-09-0((2S,3S)-pterosin Q)
• 501687-08-7(1-Propanone, 3-(2,6-dimethylphenyl)-3-hydroxy-1-phenyl-)